September 5, 2026

BSE Limited **Code: 532321** P J Towers, Dalal Street, Mumbai-400001	**National Stock Exchange of India Limited** **Code: Zyduslife** Exchange Plaza, C/1, Block G, Bandra-Kurla Complex, Bandra (East), Mumbai-400051

Sub.: **Disclosure under regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations")**

Dear Sir / Madam,

Pursuant to the provisions of regulation 30 of the Listing Regulations, we hereby inform that Zydus Pharmaceuticals USA Inc., USA ("**ZPUI**"), a wholly owned subsidiary of the Company entered into a Settlement Agreement ("the **Settlement**") with a putative class of Indirect Reseller Plaintiffs to resolve certain litigation matters proceeding as a part of MDL No. 2724 (Case No. 16-md-2724), In re Generic Pharmaceuticals Pricing Antitrust Litigation, pending in the United States District Court for the Eastern District of Pennsylvania.

Pursuant to the Settlement, ZPUI has agreed to pay a total of USD 5.9 million to resolve above litigation matters. The Settlement contains a full and final release of all claims by the Indirect Reseller Plaintiffs and was entered into without any admission of fault or wrongdoing by ZPUI.

This is for your information please.

Yours faithfully,
For, **Zydus Lifesciences Limited**

DHAVAL NARENDRA SONI
Digitally signed by DHAVAL NARENDRA SONI
Date: 2026.09.05 17:08:36 +05'30'

Dhaval N. Soni
Company Secretary and Compliance Officer
Membership No. FCS7063